Two Phase 3 Trials of Inclisiran in Patients with Elevated #LDL Cholesterol

Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin–kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing. METHODSWe enrolled patients with atherosclerotic cardiovascular disease (ORION-10 trial) and patients with atherosclerotic cardiovascular disease or an atherosclerotic cardiovascular disease risk equivalent (ORION-11 trial) who had elevated … Continue reading Two Phase 3 Trials of Inclisiran in Patients with Elevated #LDL Cholesterol